Contaminated Fibrinogen Was Given To More Than 250 In Japan Even After Warning
This article was originally published in PharmAsia News
Executive Summary
A recent survey conducted by Japan's Ministry of Health, Labor and Welfare found that even after a warning about risk of contaminated blood product Fibrinogen had been issued, the products were still administrated to more than 250 patients nationwide. In June 1988, after a group infection of hepatitis in Aomori Prefecture began to spread, the drug's maker Green Cross Corp. (currently Tanabe Mitsubishi Pharmaceuticals) distributed the emergent safety information to medical facilities and recalled the majority of the products. However, according to a recent MHLW survey, among 8,711 cases identified, 266 people were administered the product from 1989 to 1994, when the warning had been issued. Tanabe Mitsubishi estimated that the number of patients who were given Fibrinogen is roughly 288,000. (Click for more-Japanese language
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.